Zydus Cadila has gotten endorsement from the Drug Controller General of India (DCGI) for its new medication application for Saroglitazar to treat a specific state of liver, regularly known as NASH in India, the medication major said on Thursday.

The Ahmedabad-based organization said the affirmed item is the first since forever tranquilize anyplace on the planet for treatment of Non-Cirrhotic Non-Alcoholic SteatoHepatitis (NASH) which is a dynamic ailment of the liver.

The condition begins with fat collection in the liver known as non-alcoholic greasy liver ailment and progress to cirrhosis and liver disappointment.

Remarking on the endorsement, Zydus Group Chairman Pankaj Patel stated, "We are cheerful that our endeavors to find and build up a novel medication for patients living with NASH, a neglected social insurance need all around, have been effective. Saroglitazar will give trust and new rent of life for many patients in India experiencing NASH".

The organization had propelled Saroglitazar in India in September 2013 for treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with Type-2 diabetes not constrained by statins alone.

In January this year, Saroglitazar got an endorsement for the treatment of Type-2 diabetes Mellitus. Over the most recent seven years, over a million patients have profited by this medication, Zydua Cadila said.